Coagulation factor XI
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Coagulation factor XI as ChEMBL target CHEMBL2820, mapped to UniProt P03951. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Coagulation factor XI matters
Coagulation factor XI is reviewed as Coagulation factor XI (UniProt P03951); Coagulation factor XI shows approved-linked disease relevance led by hereditary angioedema. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 3720 compounds, and 266 assays, with lead potency reaching pChEMBL 10.7.
Coagulation factor XI Sequence length is 625 aa.
Review this target as Coagulation factor XI, mapped to UniProt P03951. Sequence length is 625 aa.
Protein source · UniProt accession via ChEMBL component mappingCoagulation factor XI shows approved-linked disease relevance led by hereditary angioedema. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include HUMAN C1-ESTERASE INHIBITOR.
Start review with hereditary angioedema because it currently carries approved-linked support. Linked drugs include HUMAN C1-ESTERASE INHIBITOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 3720 compounds, and 266 assays for this target. The dominant activity type is IC50. CHEMBL4096251 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL4096251 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Coagulation factor XI matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P03951, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need to see why hereditary angioedema is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4096251
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL4060950
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL4107149
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL3580759
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL4110926
|
10.4 | Ki | — |